MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- GSK PHARMA - ADCOCK INGRAM (S. Africa)
GSK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results
GSK PHARMA Change
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 GSK PHARMA  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| GSK PHARMA Mar-19 |
ADCOCK INGRAM Jun-14 |
GSK PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 3,595 | 384 | - | |
| Low | Rs | 1,253 | 277 | - | |
| Sales per share (Unadj.) | Rs | 184.7 | 114.1 | - | |
| Earnings per share (Unadj.) | Rs | 26.3 | -28.7 | - | |
| Cash flow per share (Unadj.) | Rs | 29.2 | -23.8 | - | |
| Dividends per share (Unadj.) | Rs | 20.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 126.3 | 89.5 | - | |
| Shares outstanding (eoy) | m | 169.40 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 13.1 | 2.9 | 453.7% | |
| Avg P/E ratio | x | 92.2 | -11.5 | -802.9% | |
| P/CF ratio (eoy) | x | 83.1 | -13.9 | -599.9% | |
| Price / Book Value ratio | x | 19.2 | 3.7 | 520.6% | |
| Dividend payout | % | 76.1 | 0 | - | |
| Avg Mkt Cap | Rs m | 410,626 | 55,714 | 737.0% | |
| No. of employees | `000 | 5.0 | 4.3 | 115.5% | |
| Total wages/salary | Rs m | 5,372 | 3,497 | 153.6% | |
| Avg. sales/employee | Rs Th | 6,306.7 | 4,485.3 | 140.6% | |
| Avg. wages/employee | Rs Th | 1,083.1 | 814.5 | 133.0% | |
| Avg. net profit/employee | Rs Th | 898.0 | -1,130.2 | -79.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 31,281 | 19,256 | 162.5% | |
| Other income | Rs m | 1,023 | 135 | 758.8% | |
| Total revenues | Rs m | 32,304 | 19,390 | 166.6% | |
| Gross profit | Rs m | 6,009 | -3,337 | -180.1% | |
| Depreciation | Rs m | 486 | 831 | 58.5% | |
| Interest | Rs m | 6 | 522 | 1.2% | |
| Profit before tax | Rs m | 6,540 | -4,555 | -143.6% | |
| Minority Interest | Rs m | 0 | -13 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 287 | 0 | - | |
| Tax | Rs m | 2,373 | 285 | 833.8% | |
| Profit after tax | Rs m | 4,454 | -4,852 | -91.8% | |
| Gross profit margin | % | 19.2 | -17.3 | -110.8% | |
| Effective tax rate | % | 36.3 | -6.2 | -580.7% | |
| Net profit margin | % | 14.2 | -25.2 | -56.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 20,061 | 14,103 | 142.2% | |
| Current liabilities | Rs m | 14,543 | 7,935 | 183.3% | |
| Net working cap to sales | % | 17.6 | 32.0 | 55.1% | |
| Current ratio | x | 1.4 | 1.8 | 77.6% | |
| Inventory Days | Days | 57 | 111 | 51.2% | |
| Debtors Days | Days | 14 | 124 | 11.3% | |
| Net fixed assets | Rs m | 14,343 | 8,221 | 174.5% | |
| Share capital | Rs m | 1,694 | 89 | 1,894.8% | |
| Net worth | Rs m | 21,398 | 15,114 | 141.6% | |
| Long term debt | Rs m | 2 | 5,311 | 0.0% | |
| Total assets | Rs m | 39,113 | 28,551 | 137.0% | |
| Interest coverage | x | 1,091.0 | -7.7 | -14,109.7% | |
| Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 118.6% | |
| Return on assets | % | 11.4 | -15.2 | -75.2% | |
| Return on equity | % | 20.8 | -32.1 | -64.8% | |
| Return on capital | % | 31.9 | -19.8 | -161.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,994 | 1,644 | 243.0% | |
| From Investments | Rs m | -1,433 | -505 | 284.0% | |
| From Financial Activity | Rs m | -3,584 | 4,820 | -74.3% | |
| Net Cashflow | Rs m | -1,023 | 5,959 | -17.2% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.29 Rs / ZAR
Compare GSK PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare GSK PHARMA With: ELDER PHARMA ALEMBIC PHARMA VENUS REMEDIES CIPLA SANOFI INDIA
Today's Market
Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)
Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.
Related Views On News
GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)
Oct 30, 2020 | Updated on Oct 30, 2020For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
More
